Item 1.01. Entry into a Material Definitive Agreement.
On December 12, 2016, CytoDyn Inc. (the
Company
) entered into a Securities Purchase Agreement (the
Purchase
Agreement
) with certain investors (the
Investors
) for the sale by the Company of up to 4,000,000 shares (the
Common Shares
) of the Companys common stock, par value $0.001 per share (the
Common Stock
), at a purchase price of $0.75 per share in a registered direct offering. The investors in this offering also received warrants to purchase up to 2,000,000 shares of Common Stock (the
Warrants
). The
aggregate gross proceeds for the sale of the Common Shares and Warrants will be approximately $3.0 million. Subject to certain ownership limitations, the Warrants will be exercisable commencing on the issuance date at an exercise price equal to
$1.00 per share of Common Stock, subject to adjustments as provided under the terms of the Warrants. The Warrants are exercisable for five years from the date of issuance. The closing of the sales of these securities under the Purchase Agreement is
expected to occur on or about December 12, 2016.
The net proceeds to the Company from the transactions, after deducting the Companys estimated
offering expenses, and excluding the proceeds, if any, from the exercise of the Warrants, are expected to be approximately $3.0 million. The Company intends to use the net proceeds from the transactions to fund clinical trials for its product
candidates and for general corporate purposes.
The securities sold in the offering were offered and sold by the Company pursuant to an effective shelf
registration statement on Form S-3, which was filed with the Securities and Exchange Commission (the
SEC
) on August 26, 2016 and subsequently declared effective on September 9, 2016 (File No. 333-213349) (the
Registration Statement
), and the base prospectus dated as of September 9, 2016 contained therein. The Company will file a prospectus supplement with the SEC in connection with the sale of the securities.
The representations, warranties and covenants contained in the Purchase Agreement were made solely for the benefit of the parties to the Purchase Agreement.
In addition, such representations, warranties and covenants (i) are intended as a way of allocating the risk between the parties to the Purchase Agreement and not as statements of fact, and (ii) may apply standards of materiality in a way
that is different from what may be viewed as material by stockholders of, or other investors in, the Company. Accordingly, the Purchase Agreement is included with this filing only to provide investors with information regarding the terms of
transaction, and not to provide investors with any other factual information regarding the Company. Stockholders should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of
facts or condition of the Company or any of its subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Purchase Agreement, which subsequent information
may or may not be fully reflected in public disclosures.
The forms of the Purchase Agreement and the Warrant are filed as Exhibits 10.1 and 4.1,
respectively, to this Current Report on Form 8-K. The foregoing summaries of the terms of these documents are subject to, and qualified in their entirety by, such documents, which are incorporated herein by reference.
The legal opinion and consent of Lowenstein Sandler LLP relating to the securities is filed as Exhibit 5.1 to this Current Report on Form 8-K and is
incorporated herein by reference.